A clinical briefing on the Bevacizumab (Avastin) shortage for oncologists and prescribers. Timeline, alternatives, and tools for 2026.
Bevacizumab remains one of the most widely prescribed anti-VEGF agents in oncology, with FDA-approved indications spanning seven cancer types. For providers managing patients on Bevacizumab-containing regimens, supply disruptions create real clinical challenges — from treatment delays to difficult conversations about biosimilar substitution and therapeutic alternatives.
This briefing covers the current shortage landscape, prescribing implications, and practical resources to help you keep your patients on track.
Bevacizumab supply issues have evolved significantly over the past several years:
The current multi-source landscape creates both opportunities and challenges for prescribers:
All six FDA-approved Bevacizumab biosimilars have demonstrated biosimilarity to reference Avastin through rigorous analytical, nonclinical, and clinical studies. From a clinical perspective, switching between Bevacizumab products is supported by FDA guidance and real-world evidence showing no meaningful differences in efficacy or safety.
However, institutional formulary decisions, payer contracts, and state pharmacy laws may influence which specific product is available at your facility. Maintaining familiarity with multiple biosimilar options — and ensuring your electronic ordering systems can accommodate product switches — is essential during shortage periods.
Bevacizumab dosing varies by indication:
During supply constraints, ensure dosing calculations account for the available vial sizes (100 mg/4 mL and 400 mg/16 mL) to minimize waste. Vial sharing protocols, where permitted by institutional policy and state law, can help stretch limited supply.
Short treatment delays (3-7 days) to source Bevacizumab may be clinically acceptable for many patients, though this depends on disease burden, treatment intent, and the specific regimen. Document the clinical rationale for any delay and communicate proactively with patients about the situation.
As of early 2026, the Bevacizumab market includes seven products:
Not all products are equally available at all facilities. Availability depends on GPO contracts, specialty distributor relationships, and regional distribution patterns. Facilities that maintain multi-source purchasing agreements are better positioned to weather individual product shortages.
Biosimilar competition has driven meaningful price reductions for Bevacizumab:
However, research published in JAMA (March 2026) noted that while acquisition costs for biosimilars have fallen significantly, commercial payer reimbursement rates and hospital markups can create situations where the cost savings don't fully reach patients. Be aware of your facility's specific reimbursement dynamics when counseling patients on costs.
For patients facing financial barriers, several resources exist:
Several tools can help you navigate Bevacizumab supply challenges:
When Bevacizumab cannot be sourced in any formulation, the following agents may be considered depending on indication:
Each alternative has distinct indication profiles, dosing, side effects, and evidence bases. Refer to NCCN guidelines and institutional protocols for indication-specific recommendations. For a patient-facing overview, see our alternatives to Bevacizumab guide.
Several trends suggest continued improvement in Bevacizumab access:
However, the broader drug shortage crisis — driven by fragile supply chains, limited manufacturing redundancy, and economic pressures on generic/biosimilar producers — means that intermittent disruptions are likely to continue for the foreseeable future.
Managing Bevacizumab access in 2026 requires a proactive, multi-faceted approach. Maintain relationships with multiple distributors, stay current on shortage databases, leverage tools like Medfinder for Providers, and ensure your team is prepared to substitute between biosimilar products. Most importantly, communicate openly with patients about supply situations and the safety of biosimilar switching.
For patient-facing resources you can share, see our patient shortage update and tips for finding Bevacizumab in stock.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
